Telmisartan ( DrugBank: Telmisartan )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 5 |
| 67 | Polycystic kidney disease | 2 |
66. IgA nephropathy
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100049833 | 2021-08-10 | 2021-08-10 | A single-case randomized controlled study of Huaiqihuang granules in treatment of proteinuria in IgA nephropathy | A single-case randomized controlled study of Huaiqihuang granules in treatment of proteinuria in IgA nephropathy | IgA nephropathy | control group:Telmisartan tablets;Experimental group:Huai Qi Huang Granules+Telmisartan tablets; | Xiyuan Hospital, China Academy of Chinese Medical Sciences | NULL | Pending | 18 | 50 | Both | control group:10;Experimental group:10; | N/A | China |
| 2 | ChiCTR2000040161 | 2020-11-15 | 2020-11-23 | Study on dose-effect relationship and safety of Modified Huangqi Chifeng Decoction with different doses of Astragalus in the treatment of IgA nephroproteinuria | Study on dose-effect relationship and safety of Modified Huangqi Chifeng Decoction with different doses of Astragalus in the treatment of IgA nephroproteinuria | IgA nephropathy | control group:Placebo + telmisartan tablet;Experimental group 1:Modified Huangqi Chifeng Decoction 1 + telmisartan tablet;Experimental group 2:Modified Huangqi Chifeng Decoction 2 + telmisartan tablet;Experimental group 3:Modified Huangqi Chifeng Decoction 3 + telmisartan tablet; | Xiyuan Hospital, China Academy of Chinese Medical Sciences | NULL | Pending | Both | control group:30;Experimental group 1:30;Experimental group 2:30;Experimental group 3:30; | N/A | China | ||
| 3 | ITMCTR2000004074 | 2020-11-15 | 2020-11-23 | Study on dose-effect relationship and safety of Modified Huangqi Chifeng Decoction with different doses of Astragalus in the treatment of IgA nephroproteinuria | Study on dose-effect relationship and safety of Modified Huangqi Chifeng Decoction with different doses of Astragalus in the treatment of IgA nephroproteinuria | IgA nephropathy | Experimental group 3:Modified Huangqi Chifeng Decoction 3 + telmisartan tablet;control group:Placebo + telmisartan tablet;Experimental group 1:Modified Huangqi Chifeng Decoction 1 + telmisartan tablet;Experimental group 2:Modified Huangqi Chifeng Decoction 2 + telmisartan tablet; | Xiyuan Hospital, China Academy of Chinese Medical Sciences | NULL | Pending | Both | Experimental group 3:30;control group:30;Experimental group 1:30;Experimental group 2:30; | N/A | China | ||
| 4 | ChiCTR1900022100 | 2019-04-01 | 2019-03-25 | Evaluation of clinical efficacy of Modified Huangqi Chifeng Decoction in treating IgA Nephropathy proteinuia based on Chinese medicine pathogenesis of deficiency-wind-stasis -toxin” | Evaluation of clinical efficacy of Modified Huangqi Chifeng Decoction in treating IgA Nephropathy proteinuia based on Chinese medicine pathogenesis of deficiency-wind-stasis -toxin” | IgA nephropathy | Placebo Group:Placebo+telmisartan;Experimental group:Flavoured huangqi chifeng granules+telmisartan; | Xiyuan Hospital, China Academy of Chinese Medical Sciences | NULL | Recruiting | Both | Placebo Group:40;Experimental group:40; | N/A | China | ||
| 5 | ChiCTR-TRC-10000776 | 2010-02-27 | 2010-02-10 | A Study on the Efficacy and Safety of Telmisartan, Clopidogrelin and Leflunomide in patients with IgA nephropathy | A Study on the Efficacy and Safety of Telmisartan, Clopidogrelin and Leflunomide in patients with IgA nephropathy | lgA nephropathy;ICD:N03.8 | 1:Telmisartan+ Clopidogrelin placebo + Leflunomide placebo ;2:Telmisartan + Clopidogrelin+ Leflunomide placebo ;3:Telmisartan + Clopidogrelin placebo + Leflunomide;4:Telmisartan + Clopidogrelin + Leflunomide; | Chinese General Hospital of PLA | NULL | Completed | 18 | 55 | Both | 1:100;2:100;3:100;4:100; | China |
67. Polycystic kidney disease
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01885559 (ClinicalTrials.gov) | January 2006 | 17/6/2013 | HALT Progression of Polycystic Kidney Disease Study B | HALT Progression of Polycystic Kidney Disease Study B | Kidney, Polycystic | Drug: Lisinopril;Drug: Telmisartan;Drug: Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of Medicine | Completed | 15 Years | 64 Years | All | 486 | Phase 3 | United States |
| 2 | NCT00283686 (ClinicalTrials.gov) | January 2006 | 26/1/2006 | HALT Progression of Polycystic Kidney Disease Study A | HALT Progression of Polycystic Kidney Disease Study A | Kidney, Polycystic | Drug: Lisinopril;Drug: Telmisartan;Drug: Placebo;Other: Standard Blood Pressure Control;Other: Low Blood Pressure Control | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of Medicine | Completed | 15 Years | 64 Years | All | 558 | Phase 3 | United States |